Logo

EPRX

Eupraxia Pharmaceuticals Inc.

EPRX

Eupraxia Pharmaceuticals Inc. • NASDAQ
$6.21 ▼ -0.32% (-0.02)
Market Cap $207.91 M
52w High $7.19
52w Low $2.68
Dividend Yield 0%
P/E -7.06
Volume 23.20K
Outstanding Shares 33.48M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $9.577M ▼ $-8.852M ▲ 0% $-0.24 ▲ $-8.725M ▲
Q2-2025 $0 $11.259M ▲ $-11.909M ▼ 0% $-0.33 ▼ $-11.835M ▼
Q1-2025 $0 $10.146M ▼ $-9.631M ▲ 0% $-0.3 ▼ $-9.567M ▲
Q4-2024 $0 $10.759M ▲ $-10.799M ▼ 0% $-0.21 ▼ $-10.751M ▼
Q3-2024 $0 $8.513M $-8.066M 0% $-0.17 $-8.079M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $123.782M ▲ $128.499M ▲ $5.435M ▲ $125.27M ▲
Q2-2025 $19.766M ▼ $23.596M ▼ $2.618M ▲ $22.555M ▼
Q1-2025 $27.455M ▼ $29.233M ▼ $2.2M ▼ $28.604M ▼
Q4-2024 $33.101M ▲ $34.942M ▲ $3.103M ▲ $33.405M ▲
Q3-2024 $8.662M $10.365M $2.387M $9.52M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-6.369M ▲ $-4.507M ▲ $-60.377K ▲ $73.898M ▲ $69.194M ▲ $-4.567M ▲
Q2-2025 $-8.748M ▼ $-8.315M ▼ $-166.225K ▲ $239.778K ▼ $-7.689M ▼ $-8.481M ▼
Q1-2025 $-6.767M ▲ $-6.003M ▼ $-169.044K ▼ $429.923K ▼ $-5.647M ▼ $-6.172M ▼
Q4-2024 $-7.532M ▼ $-5.972M ▲ $-43.757K ▼ $31.731M ▲ $24.439M ▲ $-6.017M ▲
Q3-2024 $-5.991M $-10.19M $-42.275K $-4.601M $-14.654M $-10.232M

Five-Year Company Overview

Income Statement

Income Statement Eupraxia looks like a classic clinical‑stage biotech on the income side: no meaningful revenue yet and a history of annual losses. The company is spending money ahead of potential product approvals, mainly on research, clinical trials, and overhead, without any commercial products to offset those costs. Losses per share have been fairly sizable and persistent, which is typical for a company still proving out its science but means profitability is not on the near‑term horizon and will likely depend on successful trial results and eventual product launches or deals.

Balance Sheet

Balance Sheet The balance sheet is small and simple. Assets are modest and largely made up of cash, with very limited tangible infrastructure. Debt has been low and recently appears to have been reduced, which lowers financial pressure but does not remove the need for future funding. Shareholders’ equity has swung from negative to positive over the years, reflecting capital raises and ongoing losses. Overall, the company appears lightly leveraged but financially fragile, relying on its cash reserves and access to capital markets rather than on internally generated funds.

Cash Flow

Cash Flow Cash flow reflects steady cash burn from operations, driven by R&D and operating expenses, with almost no spending on long‑term physical assets. Free cash flow has been consistently negative, and there is no inflow from product sales to refill the cash balance. This means the business depends on external financing—such as equity raises, grants, or partnerships—to sustain its pipeline. The key risk is how long existing cash can support clinical programs before additional funding is required, especially if development timelines slip.

Competitive Edge

Competitive Edge Competitively, Eupraxia is trying to carve out a niche with its Diffusphere extended‑release drug delivery platform. The focus on localized, long‑acting delivery of proven drugs could provide meaningful advantages in safety, convenience, and durability of effect, especially in conditions like osteoarthritis of the knee and eosinophilic esophagitis where current treatments have limitations. Patents and proprietary know‑how provide a legal and technical barrier to direct copycats. However, the company faces intense competition from larger, well‑funded pharma players and existing therapies, and it still needs robust late‑stage clinical and real‑world data to convert its scientific edge into a durable commercial position.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of the story. The Diffusphere platform is designed to be flexible and reusable across multiple drugs and diseases, which, if validated, can turn each successful program into proof of concept for the entire platform. Lead candidates targeting osteoarthritis pain and eosinophilic esophagitis demonstrate how the same technology can be applied to both joints and the gastrointestinal tract. The company is also signaling future uses in pain management, infection control, oncology, and even veterinary medicine. This platform approach creates upside if trials succeed, but it also concentrates risk: setbacks in key studies could undermine confidence in the broader R&D strategy and require significant time and capital to recover.

Summary

Eupraxia is an early‑stage biotech with a promising but unproven drug‑delivery platform, no current product revenue, and ongoing cash burn typical of its development phase. Financially, it is lean, lightly indebted, and dependent on external funding to advance its pipeline. Strategically, it is aiming at well‑defined unmet needs with a differentiated technology and a growing patent estate, which could support a strong position if clinical and regulatory milestones are met. The main uncertainties lie in trial outcomes, regulatory approvals, competitive responses, and the company’s ability to secure sufficient funding and partnerships to carry its programs from the lab to the marketplace.

NEWS

November 13, 2025 · 5:00 PM UTC

Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI

Read more

November 4, 2025 · 4:39 PM UTC

Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results

Read more

September 29, 2025 · 5:00 PM UTC

Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs

Read more

September 24, 2025 · 8:54 AM UTC

Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option

Read more

September 22, 2025 · 10:42 PM UTC

Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares

Read more